AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 MAY 29 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - The authors of a new study have concluded AM3 (Inmunoferon) enhances the ability of kidney disease patients on hemodialysis to develop long-term protective immunity against hepatitis B virus (HBV) infection after their receiving HBV vaccine.
"Patients with end-stage renal disease undergoing hemodialysis have severe alterations in cell-mediated immunity that increases their risk of contracting chronic HBV infection and decreases their protective responses to HBV vaccine," Rafael Perez-Garcia, Gregorio Maranon Hospital, Madrid, Spain, described in Kidney International.
For that reason, Perez-Garcia and colleagues studied whether or not AM3, an immune system modulator that stimulates humoral response, had the ability to boost HBV vaccine effectiveness in kidney disease patients on long-term dialysis.
The authors of the multicenter vaccine trial administered a four dose regimen of DNA recombinant vaccine to more than 200 study participants. On the 15th day before the first vaccine dose was administered, study volunteers began taking AM3 or a placebo for a period of a month.
"The placebo and AM3-treated groups had comparable seroconversion and protective response rates 1 month after the final vaccine dose," Perez-Garcia and ...
Source: HighBeam Research, Agent renders hepatitis B vaccine more effective in hemodialysis...